The density of CSF-1R+ TAMs in tumors correlates with poor outcomes in many tumor types, including colon adenocarcinoma, pancreatic cancer, classical Hodgkin lymphoma, leiomyosarcoma, hepatocellular carcinoma and breast cancer (81–86). This evidence concerns the gene CSF1R and classic Hodgkin lymphoma.